Enzymicals AG has extended its patent application for a biocatalytic synthesis of a chiral intermediates for the drug sitagliptin. This process uses a new enzyme that was discovered to catalyze the synthesis of (R)-3-amino-4-aryl-butanoic acid derivatives with high enantioselectivity and efficiency. The extension was made to five continents by PCT application. We hope that our invention will contribute to the development of more sustainable and affordable pharmaceuticals.
Contact us when you want to discuss licensing and/or collaborations to develop this technology for commercial applications.
